Truncated neurokinin‑1 receptor is an ubiquitous antitumor target in hepatoblastoma, and its expression is independent of tumor biology and stage

Garnier,Agnès; Ilmer,Matthias; Becker,Kristina; Häberle,Beate; Schweinitz,Dietrich Von; Kappler,Roland; Berger,Michael

doi:10.3892/ol.2015.3951

Truncated neurokinin‑1 receptor is an ubiquitous antitumor target in hepatoblastoma, and its expression is independent of tumor biology and stage

Authors:
- Agnès Garnier
- Matthias Ilmer
- Kristina Becker
- Beate Häberle
- Dietrich Von Schweinitz
- Roland Kappler
- Michael Berger
View Affiliations

Affiliations: Department of Pediatric Surgery, Dr von Hauner Children's Hospital, Ludwig Maximilian University of Munich, D‑80337 Munich, Germany, Department of General, Visceral, Transplantation, Vascular and Thoracic Surgery, Hospital of the Ludwig Maximilian University of Munich, D‑80336 Munich, Germany
Published online on: November 20, 2015 https://doi.org/10.3892/ol.2015.3951
Pages: 870-878

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The substance P (SP; also known as TAC1)/neurokinin‑1 receptor (NK1R; also known as TACR1) complex is a critical part in the development of cancer. Therefore, NK1R antagonists, such as the clinical drug aprepitant, are currently under investigation as future anticancer agents. In a previous study, NK1R (TACR1) was identified as a potent anticancer target in hepatoblastoma (HB). However, little is known regarding the exact distribution of this target among HB subsets and whether it correlates with clinical features and prognosis. In the present study, mRNA was isolated from 47 children with HB, and reverse transcription‑quantitative polymerase chain reaction was performed on the samples to analyze the expression of full‑length‑TACR1 (fl‑TACR1) and truncated‑TACR1 (tr‑TACR1). These data were correlated with data obtained from 9 tumor‑free controls, as well as with the presence of metastasis, PRETEXT, vascular invasion, histology, age of diagnosis, multifocality, CTNNB1 mutation, gender and overall survival. Additionally, the present study investigated a recently described 16‑gene signature characterizing HB known to correlate with prognosis. Compared with tumor‑free liver tissue, tumorous tissue expressed TACR1 significantly higher for the truncated version (P=0.0301), and by trend also for the full‑length version. Accordingly, the expression of fl‑TACR1 correlated with the expression of the truncated version (P=0.0074). Furthermore, a low expression of fl‑TACR1 correlated with characteristics of the 16‑gene signature known to predict prognosis (P=0.0222). However, there was no correlation between tr‑TACR1 and the tumor characteristics investigated, including outcome, although a clear trend was observed for some tumor characteristics. The current results reinforced the previously described findings that in HB, tr‑TACR1 is overexpressed compared with tumor‑free liver tissue. Furthermore, to the best of our knowledge, the present study demonstrated for the first time that tr‑TACR1 is expressed ubiquitously among the different subsets of HB. Therefore, NK1R may serve as a potent anticancer target in a large variety of patients with HB, independent of tumor biology and clinical stage.

View Figures

View References

1	von Schweinitz D: Hepatoblastoma: Recent developments in research and treatment. Semin Pediatr Surg. 21:21–30. 2012. View Article : Google Scholar : PubMed/NCBI
2	Haeberle B and Schweinitz D: Treatment of hepatoblastoma in the German cooperative pediatric liver tumor studies. Front Biosci (Elite Ed). 4:493–498. 2012. View Article : Google Scholar : PubMed/NCBI
3	Warmann S, Hunger M, Teichmann B, et al: The role of the MDR1 gene in the development of multidrug resistance in human hepatoblastoma: Clinical course and in vivo model. Cancer. 95:1795–1801. 2002. View Article : Google Scholar : PubMed/NCBI
4	Muñoz M, Rosso M and Coveñas R: The NK-1 receptor: A new target in cancer therapy. Curr Drug Targets. 12:909–921. 2011. View Article : Google Scholar : PubMed/NCBI
5	Palma C, Bigioni M, Irrissuto C, et al: Anti-tumour activity of tachykinin NK1 receptor antagonists on human glioma U373 MG xenograft. Br J Cancer. 82:480–487. 2000.PubMed/NCBI
6	Rosso M, Muñoz M and Berger M: The role of neurokinin-1 receptor in the microenvironment of inflammation and cancer. ScientificWorldJournal. 2012:3814342012. View Article : Google Scholar : PubMed/NCBI
7	Muñoz M, Rosso M and Coveñas R: A new frontier in the treatment of cancer: NK-1 receptor antagonists. Curr Med Chem. 17:504–516. 2010. View Article : Google Scholar : PubMed/NCBI
8	Berger M, Neth O, Ilmer M, et al: Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo. J Hepatol. 60:985–994. 2014. View Article : Google Scholar : PubMed/NCBI
9	Muñoz M, Pérez A, Rosso M, Zamarriego C and Rosso R: Antitumoral action of the neurokinin-1 receptor antagonist L-733 060 on human melanoma cell lines. Melanoma Res. 14:183–188. 2004. View Article : Google Scholar : PubMed/NCBI
10	Mayordomo C, García-Recio S, Ametller E, et al: Targeting of substance P induces cancer cell death and decreases the steady state of EGFR and Her2. J Cell Physiol. 227:1358–1366. 2012. View Article : Google Scholar : PubMed/NCBI
11	Muñoz M, Berger M, Rosso M, et al: Antitumor activity of neurokinin-1 receptor antagonists in MG-63 human osteosarcoma xenografts. Int J Oncol. 44:137–146. 2014.PubMed/NCBI
12	Kramer MS, Cutler N, Feighner J, et al: Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science. 281:1640–1645. 1998. View Article : Google Scholar : PubMed/NCBI
13	Gillespie E, Leeman SE, Watts LA, et al: Truncated neurokinin-1 receptor is increased in colonic epithelial cells from patients with colitis-associated cancer. Proc Natl Acad Sci USA. 108:17420–17425. 2011. View Article : Google Scholar : PubMed/NCBI
14	Ramkissoon SH, Patel PS, Taborga M and Rameshwar P: Nuclear factor-kappaB is central to the expression of truncated neurokinin-1 receptor in breast cancer: Implication for breast cancer cell quiescence within bone marrow stroma. Cancer Res. 67:1653–1659. 2007. View Article : Google Scholar : PubMed/NCBI
15	Patel HJ, Ramkissoon SH, Patel PS and Rameshwar P: Transformation of breast cells by truncated neurokinin-1 receptor is secondary to activation by preprotachykinin-A peptides. Proc Natl Acad Sci USA. 102:17436–17441. 2005. View Article : Google Scholar : PubMed/NCBI
16	Cairo S, Armengol C, De Reyniès A, et al: Hepatic stem-like phenotype and interplay of Wnt/β-catenin and Myc signaling in aggressive childhood liver cancer. Cancer Cell. 14:471–484. 2008. View Article : Google Scholar : PubMed/NCBI
17	Cairo S, Armengol C and Buendia MA: Activation of Wnt and Myc signaling in hepatoblastoma. Front Biosci (Elite Ed). 4:480–486. 2012. View Article : Google Scholar : PubMed/NCBI
18	Garcia-Recio S, Fuster G, Fernandez-Nogueira P, et al: Substance P autocrine signaling contributes to persistent HER2 activation that drives malignant progression and drug resistance in breast cancer. Cancer Res. 73:6424–6434. 2013. View Article : Google Scholar : PubMed/NCBI
19	Esteban F, Muñoz M, González-Moles MA and Rosso M: A role for substance P in cancer promotion and progression: A mechanism to counteract intracellular death signals following oncogene activation or DNA damage. Cancer Metastasis Rev. 25:137–145. 2006. View Article : Google Scholar : PubMed/NCBI
20	Esteban F, Gonzalez-Moles MA, Castro D, et al: Expression of substance P and neurokinin-1-receptor in laryngeal cancer: Linking chronic inflammation to cancer promotion and progression. Histopathology. 54:258–260. 2009. View Article : Google Scholar : PubMed/NCBI
21	Castro TA, Cohen MC and Rameshwar P: The expression of neurokinin-1 and preprotachykinin-1 in breast cancer cells depends on the relative degree of invasive and metastatic potential. Clin Exp Metastasis. 22:621–628. 2005. View Article : Google Scholar : PubMed/NCBI
22	Misawa K, Kanazawa T, Misawa Y, et al: Frequent promoter hypermethylation of tachykinin-1 and tachykinin receptor type 1 is a potential biomarker for head and neck cancer. J Cancer Res Clin Oncol. 139:879–889. 2013. View Article : Google Scholar : PubMed/NCBI
23	Pritchard J, Brown J, Shafford E, et al: Cisplatin, doxorubicin, and delayed surgery for childhood hepatoblastoma: A successful approach - results of the first prospective study of the International Society of Pediatric Oncology. J Clin Oncol. 18:3819–3828. 2000.PubMed/NCBI
24	Roebuck DJ, Aronson D, Clapuyt P, et al: International Childrhood Liver Tumor Strategy Group: PRETEXT: A revised staging system for primary malignant liver tumours of childhood developed by the SIOPEL group. Pediatr Radiol. 37:123–132; quiz 249–150. 2007. View Article : Google Scholar : PubMed/NCBI
25	Eichenmüller M, Trippel F, Kreuder M, et al: The genomic landscape of hepatoblastoma and their progenies with HCC-like features. J Hepatol. 61:1312–1320. 2014. View Article : Google Scholar : PubMed/NCBI
26	Eichenmüller M, Gruner I, Hagl B, Häberle B, Müller-Höcker J, von Schweinitz D and Kappler R: Blocking the hedgehog pathway inhibits hepatoblastoma growth. Hepatology. 49:482–490. 2009. View Article : Google Scholar : PubMed/NCBI
27	Bigioni M, Benzo A, Irrissuto C, Maggi CA and Goso C: Role of NK-1 and NK-2 tachykinin receptor antagonism on the growth of human breast carcinoma cell line MDA-MB-231. Anticancer Drugs. 16:1083–1089. 2005. View Article : Google Scholar : PubMed/NCBI
28	Pfaffl MW: A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 29:e452001. View Article : Google Scholar : PubMed/NCBI
29	Muñoz M and Coveñas R: Neurokinin-1 receptor: A new promising target in the treatment of cancer. Discov Med. 10:305–313. 2010.PubMed/NCBI
30	Muñoz M and Rosso M: The NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drug. Invest New Drugs. 28:187–193. 2010. View Article : Google Scholar : PubMed/NCBI
31	Nault JC and Villanueva A: Intratumor molecular and phenotypic diversity in hepatocellular carcinoma. Clin Cancer Res. 10:1786–1788. 2015. View Article : Google Scholar